Cytotoxicity of Dhanwantharaarishtam on hiPSC Cells – An In vitro Study Authors: Barri Indira Devi, J. Kalaivannan, Sumathi Jones, C.S. Janaki, Dhastagir Sheriff, K. Prabhu, Deepalakkshmi Balakrishnan, Shyamala Sambasivam Published: 2024 ABSTRACT ABSTRACTBackground:Dhanwantharaarishtam is a traditional Ayurvedic herbal tonic used to improve digestion, promote lactation, and balance the Vata dosha.Aim:The study investigates the effects of Dhanwantharaarishtam, a traditional Ayurvedic tonic, on cell viability and cytotoxicity in human induced pluripotent stem cell (hiPSC) cultures.Methods:The impact of Dhanwantharaarishtam on hiPSC cells was analyzed over a 24 hour period.Results:Our results reveal significantly less cytotoxicity, with 80.1 ± 6.7% cell viability observed at 500 µg concentrations. Conversely, cell viability was reduced to 50.3 ± 4.15% at 1000 µg concentration.Conclusion:These findings suggest that while Dhanwantharaarishtam exhibits potent biological effects, including potential therapeutic benefits, its unsubstantial cytotoxic profile in hiPSC cells necessitates further investigation to elucidate its safety and potential applications in clinical settings. This study underscores the importance of rigorous evaluation of traditional herbal remedies for their efficacy and safety in modern biomedical research. INTRODUCTION Dhanwantharaarishtam is a traditional Ayurvedic herbal tonic renowned for its rejuvenative and therapeutic properties, particularly in supporting women’s health post childbirth. Formulated with a blend of medicinal herbs such as Dashamoola (ten roots), Ashwagandha (Withania somnifera), and Manjistha (Rubia cordifolia), it is primarily used to enhance recovery, improve digestion, promote lactation, and balance the Vata dosha. This fermented preparation allows for the effective extraction and preservation of the medicinal properties of the herbs, making it a valuable remedy in Ayurvedic medicine.[1] Clinical studies have suggested that Dhanwantharaarishtam may possess anti-inflammatory and antioxidant properties.[2] Research indicates that the formulation can help reduce inflammation and oxidative stress, potentially contributing to its therapeutic effects in various conditions, mainly stroke. METHODOLOGY Cell lines Human-induced pluripotent stem cells (hiPSCs) were only used for both cell viability and cytotoxic studies The hiPSC used in this study was obtained from National Centre for Cell Sciences (NCCS), Pune, India. Cell culture hiPSCs cultured in a minimal essential medium (MEM) with Earl’s salts (EMEM) were supplemented with 10% fetal bovine serum (FBS), 1% nonessential amino acids (NEAAs), 2 mM L-glutamine, and 1% penicillin–streptomycin to ensure optimal growth conditions. The cells were then seeded at a density of 500 cells per mm² in 96-well plates to facilitate uniform cell distribution and allowed to adhere overnight to establish a stable culture. Then the initial growth medium was swapped with a differentiation medium designed to promote the transformation of hiPSCs into specialized cells consisting of a 1:1 mixture of Dulbecco’s modified Eagle’s medium (DMEM) and Ham’s F12, further with 1% N2 supplementation and 1% penicillin–streptomycin to provide essential nutrients and maintain sterility. Additionally, 1 μM retinoic acid (RA) was included in the medium to induce the differentiation process. The differentiation process was maintained for a duration of 3 to 6 days. During this period, the medium was refreshed every 48 hours by replacing half of the existing medium with a fresh differentiation medium. This regular medium change helped maintain the necessary nutrient levels and remove metabolic waste products, thereby supporting optimal cell differentiation and growth. Oxygen-glucose deprivation and reperfusion For ischemic stroke modeling in vitro, first, the cells were washed with a glucose-free medium. hiPSC-derived neurons (hiPSC-neurons) were then incubated in glucose-free DMEM within an oxygen-controlled CO2 incubator set to maintain conditions of 1% O2, 5% CO2, and 94% N2 at 37°C for 24 hours. This setup induced oxygen-glucose deprivation (OGD). Following the OGD treatment, the cells underwent reperfusion by replacing the glucose-free medium with a glucose-containing maturation medium. The cells were then incubated for 24 to 72 hours at 37°C in an environment of 95% air and 5% CO2. Control hiPSC-neurons were subjected to similar washing and incubation procedures and maintained in ND3 medium and glucose-containing maturation medium under normal oxygen conditions, which consisted of 95% air and 5% CO2, for 24 hours. Preparation of test solution A sterilized stock solution of Dhanwanthararaarishtam 1000 μg/ml concentration was prepared. From this stock solution, different lower dilutions (10–100 μg/ml) were obtained using distilled water. Experimental groups The hiPSC cell cultures were washed with DMEM, and then the cells were then exposed to oxygen deprivation and reperfusion after 24 hours of incubation of the cultures and treated with Dhanwantharaarishtam (100–500 μg/ml) for 24 hours and then assessed to identify potential neuroprotective effects against the stroke model. The negative control group, hiPSC cells, was without any treatment. Cells in the stroke model + Dhanwantharaarishtam group were then exposed to oxygen deprivation and reperfusion and then treated with different concentrations of Dhanwantharaarishtam. For comparison with the standard, the cells treated with Alteplase (2 mg) were incubated for 2 hours. Cell viability assay The MTT assay is a colorimetric test that measures the formation of purple formazan by mitochondrial succinate dehydrogenase. The hiPSC cells were seeded at a density of 2 × 105 cells/well in 96-well plates and treated with Dhanwantharaarishtam and a standard for 24 hours. After allowing cells to adhere, the growth medium was separated, and cells were washed with MEM without FBS. A medium containing different dilutions of the drug was added, followed by 20 μl of MTT [5 mg/ml in phosphate-buffered saline (PBS)] per well. Cells were incubated for 6–7 hours in a 5% CO2 incubator. After removing the medium, 1 ml of dimethyl sulfoxide (DMSO) was added to each well to solubilize the formazan product. The cell viability was calculated by the absorbance value at 570 nm using an ELISA reader. Concentrations of Dhanwantharaarishtam ranging from 50 to 500 μg/ml were tested for evaluating its effectiveness in stroke; hence, 1000 mg was not considered. The IC50 was calculated using the formula given below. Each experiment was performed in triplicate.[34] The viable cell concentration (%) was calculated with the expression stated below. Viability (%) = [Mean Test OD/Mean Control OD] × 100 Cytotoxicity study hiPSCs were cultured in 96-well plates at a density of 3 × 10^5 cells per well for the assay. After 24 hours, the growth medium was removed, and the cells were washed twice with MEM without FBS to eliminate dead cells and any residual FBS. Then various concentrations (50 to 1000 μg/ml) of Dhanwantharaarishtam solution were added to the wells. Subsequently, 20 μl of MTT solution (5 mg/ml in PBS) was added to each well. The cells were then incubated for 6–7 hours in a 5% CO2 incubator at 37°C to allow the MTT to be metabolized to formazan by viable cells. After the incubation period, the medium was carefully discarded, and 1 ml of DMSO was added to each well to dissolve the formazan crystals formed by the metabolically active cells. To ensure complete solubilization of the formazan, 50 μl of propanol was subsequently added to each well. The absorbance of each well was measured at 570 nm using an ELISA reader, which quantified the amount of formazan and thus the number of viable cells. Each experiment was performed in triplicate to ensure accuracy and reproducibility. The IC50 value (the concentration of Dhanwantharaarishtam required to inhibit cell viability by 50%) was calculated based on the cell viability data obtained from the absorbance measurements. RESULTS The viability of hiPSC-neurons was assessed following treatment with Dhanwantharaarishtam. As shown in Table 1, the live hiPSC-neurons percentage significantly reduced in the 24-hour reperfusion group in comparison to the control group. However, treatment with Dhanwantharaarishtam significantly elevated the percentage of live cells during the oxygen deprivation model [Figure 1]. The efficacy of Dhanwantharaarishtam was also compared to that of the standard treatment, demonstrating its potential protective effect on cell viability under these conditions. Table 1MTT assay of hiPSC cells treated with DhanwantharaarishtamTreatmentConc (µg)Cell viability (%)hiPSC untreated cells-100.0±5.1Oxygen reperfusion (stroke)-21.6±1.8###hiPSC + DAN5036.5±3.9***hiPSC + DAN10048.9±3.4***hiPSC + DAN25069.4±5.8***hiPSC + DAN50080.1±6.7***hiPSC + STD2 mg85.7±7.4***Values are expressed as mean±SEM (n=3). ###P<0.001, as compared with hiPSC cells untreated control. ***P<0.001, as compared with stroke model. DAN – Dhanwantharaarishtam; STD-Alteplase MTT assay of hiPSC cells treated with Dhanwantharaarishtam Values are expressed as mean±SEM (n=3). ###P<0.001, as compared with hiPSC cells untreated control. ***P<0.001, as compared with stroke model. DAN – Dhanwantharaarishtam; STD-Alteplase Dhanwantharaarishtam showed neuroprotective effects on hiPSC-neurons after oxygen deprivation and reperfusion Cytotoxicity study The study reveals the cytotoxic and cell viability effects of Dhanwantharaarishtam on hiPSC cells using the MTT assay [Table 1]. The results demonstrate significantly less cytotoxic effects, with 85.7 ± 7.4% cell viability at 500 μg in the MTT assay, and the cell viability was found to be 50.3 ± 4.15% at 1000 μg concentration of Dhanwantharaarishtam, indicating that Dhanwantharaarishtam has a considerable impact on hiPSC cells. The initial therapeutic dose facilitated revival of oxygen-deprived cells. However, a further increase in dose or lethal dose induced apoptosis of the cell, leading to the decrease in cell viability. These findings [Table 2] suggest that while Dhanwantharaarishtam may possess potent biological activity, its cytotoxic effects on hiPSC cells warrant further investigation to better understand its safety profile and therapeutic potential. This herbal concoction is fermented, which enhances the bioavailability of its active compounds, making it a potent remedy for various health issues. Dhanwantharaarishtam is traditionally used to promote recovery after childbirth, improve digestion, enhance lactation, and balance the Vata dosha. Additionally, it exhibits anti-inflammatory, antioxidant, and immunomodulatory properties, contributing to its efficacy in supporting overall health and vitality.[5] It comprises a blend of medicinal herbs like Dashamoola, Ashwagandha, and Manjistha, fermented to enhance bioavailability and efficacy. Studies have shown its effectiveness in promoting recovery post childbirth, improving digestion, enhancing lactation, and balancing the Vata dosha.[1] However, recent research also highlights its cytotoxic effects on hiPSC cells, with significantly lesser cell death observed in vitro. Further investigation into its safety and precise mechanisms of action is crucial for optimizing its therapeutic use. Table 2Cytotoxicity assay of hiPSC cells treated with DhanwantharaarishtamTreatmentConc (µg/ml)Cell viability (%)hiPSC cells-100.0±6.7hiPSC + DAN5095.8±9.8hiPSC + DAN10089.4±7.2hiPSC + DAN25068.4±6.1hiPSC + DAN50058.9±5.86hiPSC + DAN100050.3±4.15Values are expressed as mean±SEM (n=3). The IC50 of the DAN is 1 mg Cytotoxicity assay of hiPSC cells treated with Dhanwantharaarishtam Values are expressed as mean±SEM (n=3). The IC50 of the DAN is 1 mg CONCLUSION Dhanwantharaarishtam demonstrates significant cytotoxicity toward hiPSC cells, resulting in 80.1 ± 6.7% cell viability at 500 μg and reducing the cell viability to 50.3 ± 4.15% at 1000 μg concentrations. These findings highlight the potent biological effects of this Ayurvedic tonic, underscoring the need for further research to explore its therapeutic potential in biomedical applications. Conflicts of interest There are no conflicts of interest.